Clinical Corner: Herb-Drug Interactions in Cancer Chemotherapy: Theoretical Concerns Regarding Drug Metabolizing Enzymes Keith I. Block, MD, and Charlotte Gyllenhaal, PhD Interactions between herbal medicines and conventional drugs have recently been reported; the most significant herb with such drug interactions is Saint John's wort, an inducer of cytochrome P450 3A3/4, an enzyme responsible for clearance of many clinically important drugs from the body. Foods (especially grapefruit) and habits or lifestyle factors such as smoking or alcohol consumption may also alter the metabolism of drugs through effects on the cytochrome P450 system. The authors review here the functioning of the drug-metabolizing enzymes and discuss their particular significance in cancer chemotherapy treatment. They then present the herbal medicines, foods, and lifestyle factors that induce or inhibit drug-metabolizing enzymes that are important for both cancer chemotherapy drugs and drugs used adjunctively in cancer treatment. It is notable that no actual herb-drug interactions have been reported clinically in cancer treatment, and their potential for interaction still must be regarded as theoretical. Although some chemotherapy patients may be interested in taking herbal medicines that could potentially interact with cancer chemotherapy agents, it may be wise to counsel them to use other means of addressing the problems for which they use specific herbs during the time they receive chemotherapy.
Early in 2000, the medical community was confronted by the news that a popular herbal medicine, Saint John's wort (SJW; Hypericum perforatum L., Hypericaceae), had been shown to have clinically significant interactions with some widely used drugs. Discussions of case reports of interactions with theophylline' and cyclosporine2 and reports of interactions with digoxin~ 1 and indinavir4 appeared in national news magazines as well as in medical journals. Although these publications triggered a number of overly alarmist speculations about the dangers of all herbal medicines, they also focused attention on dimensions of the biological activities of herbs and plant-derived dietary supplements that had been substantially neglected in the past. One of the most important of these was the role of inducers and inhibitors of the cytochrome P450 family of drug-metabolizing enzymes. Because integrative cancer therapies may employ drugs meta-bolized by these enzymes, and foods or herbs that alter their function, it is important that health professionals in this field understand the mechanisms and consequences of potential interactions. The interactions we will discuss in this article are all so far theoretical. No case reports exist of natural agents interacting with drugs used in cancer treatments, to the best of our knowledge. Because of the life-threatening nature of cancer, however, caution with potentially interacting agents is warranted.
Functions of Phase I (Cytochrome P450) and Phase II Enzymes
Metabolism Through Enzymes Metabolism of drugs and other xenobiotics (or chemical substances that enter the body from without) is accomplished in part through a series of enzymes referred to as phase I and phase II enzymes.&dquo; These occur primarily in the liver and are also found in some other tissues. The phase I enzymes frequently accomplish the biotransformation of drugs by structurally changing the functional groups that are responsible for their activity. These transformations are achieved through a variety of chemical reactions including hydrolysis, hydroxylation, oxidation, and reduction. The effect on the drug's activity depends on the nature of the drug. Some important chemotherapy drugs (e.g., cyclophosphamide, ifosfamide) are introduced into the body as prodrugs, whose structure must be altered by phase I enzymes to become active against cancer cells. Drugs that are introduced into the body in their active forms, on the other hand, are de-activated by phase I enzymes as a part of the process of their clear-ance or removal from the body. Phase I enzymes have also been of interest in the study of carcinogenesis because they can activate certain carcinogens; substances that increase their activity, such as charcoal-grilled meats, are suspected of being co-carcinogens. Substances that inhibit these enzymes are considered to be anticarcinogenic.' Phase II enzymes accomplish a different chemical process, referred to as conjugation. In conjugation, a new chemical entity is attached to a drug's functional group to make the drug more polar, facilitating its removal from the body. Among the chemical entities that are conjugated to drugs are some sulfur-containing compounds and glucuronic acid. Phase II enzymes are considered to have a significant role in disabling and exporting chemical carcinogens. Natural substances found in broccoli and other cruciferous vegetables (e.g., cabbage family, including Brussels sprouts, kale, mustard greens, cauliflower, etc.) increase the activity of phase II enzymes; they are thus important as anticarcinogenic agents.' From the viewpoint of drug pharmacokinetics, phase II enzymes are usually regarded as not being ratelimiting in the breakdown of drugs. Phase II enzymes, however, may be of interest in other contexts for integrative cancer medicine, particularly in the area of efficient removal of chemotherapy drug metabolites that have been de-activated after their cytotoxic effect, a topic that will not be addressed in this article. It is important to note that not all drugs go through the phase II metabolizing enzymes; many are removed after metabolism by phase I cytochrome P450 enzymes. The activities of phase I and phase II enzymes on active drugs and prodrugs are summarized in Table 1 .
The Cytochrome P450 Drug-Metabolizing Enzymes There are many types of cytochrome P450 (CYP450) enzymes that metabolize drugs; they are grouped into classes or families. Most drugs that are metabolized by these enzymes are substrates of the families CYP1, CYP2, and CYP3, the largest number being metabolized by the CYP3 group.&dquo; Individual enzymes in these families are given alphanumeric names. Thus, the phase I enzyme most involved in drug metabolism is CYP3A4, which metabolizes more than 50% of the drugs that are substrates of the CYP enzymes. The next most active enzyme is CYP2D6.
The activity of CYP450 enzymes can be affected by a number of factors. Genetic deficiencies of certain enzymes (such as CYP2D6) are known.' Persons with liver disease may have insufficient levels of some enzymes.
Age, gender, stress, pregnancy, and intake of substances that stimulate or suppress the activity of these enzymes can affect drug metabolism. The CYP450 Table 1 .
Functions of Phase I and Phase 11 Enzymes on
Prodrugs and Drugs Administered in Active Form system is quite complicated, though, and we do not know the clinical significance of all these factors. LeMarchand et al., for instance, surveyed CYP1A2 activity in 90 Hawaiians of different ethnic background.&dquo; Using as variables plasma lutein, lycopene, and alpha-tocopherol, as well as intake of alcohol, caffeine, aceta-minophen, hormonal replacement therapy, and a variety of other nutritional characteristics, these investigators were able to explain only 27% of the variance in CYP1A2 activity; 73% of variance remained unexplained. The authors suggested that acetaminophen and coffee enhanced CYP1A2 activity, whereas estrogen, alcohol, and foods containing lutein and alpha-tocopherol inhibited it. But due to the large number of other factors, including unknown factors that inhibit or enhance CYP450 activity, it was felt difficult to be certain that these effects are of great clinical relevance. needs to be activated by a CYP450 enzyme, an excess of the enzyme, brought about by induction, might result in higher levels of toxicity as the prodrug would be activated more quickly than anticipated, although this has not been shown clinically. More important for prodrugs, if the activity of the metabolizing enzyme has been inhibited, the anticipated drug level may be low as the prodrug may not become fully activated, resulting in treatment failure. Higher or unexpected toxicity could result, also, if the prodrug itself is toxic.
For a drug administered in the active form, which the CYP450 enzyme deactivates, the consequences of enzyme induction and inhibition will be the opposite to those for prodrugs. If a metabolizing enzyme has been induced, the drug will deactivate it more quickly, and a suboptimal dose and treatment failure could result. If the enzyme has been inhibited, on the other hand, the drug may not be deactivated and cleared normally, blood levels of the drug may remain high for too long a time, and toxicity may result. This was seen in a study by Hirth et al., in which the levels of CYP450 activity were measured by the erythromycin breath test in 22 cancer patients receiving docetaxel.&dquo; Patients with low CYP3A4 activity (corresponding to an inhibited status) had higher levels of grade 3 or 4 leukopenia, and grade 4 stomatitis, than patients with higher levels of CYP3A4. The 2 patients with the lowest levels of CYP3A4 activity were hospitalized for toxicity. On the other hand, the 4 patients in the study who met the criteria for partial remission also had lower CYP3A4 activity, and thus, presumably, higher docetaxel levels. Optimization of treatment with chemotherapeutic drugs depends on setting drug dosage levels at a point in relation to enzyme activities that balances the need for sufficient blood levels of drug with the need to avoid toxicity. Intake of substances that induce or inhibit CYP450 enzymes beyond what is expected in patient populations on which drug dosages may have been calibrated might upset this balance, resulting in failure of treatment or toxicity.
Recognized Inducers and Inhibitors of CYP450 Enzymes
Phytomedicines The phytomedicine that sparked recent interest in herb-drug interactions, SJW, was found to be an inducer of the important drug-metabolizing enzymes CYP3A4 and CYPlA2. ' As is true with most other recognized inducers and inhibitors, SJW induces only specific CYP450 enzymes. It will thus have the potential to affect only drugs metabolized by that enzyme. What are some of the other recognized inducers and inhibitors? As mentioned above, grapefruit juice is a well-known inhibitor of CYP3A4 and of CYP2E1, and warnings about food-drug interactions involving grapefruit juice are commonly given to patients taking affected drugs. Charcoal-grilling of meat and cigarette smoking both induce CYP1A1 and CYP1A2.&dquo;'' The latter is involved in carcinogenesis, but also in the metabolism of tamoxifen. Some flavonoids induce, whereas some inhibit CYP1A2.'~ Cruciferous vegetables and their indole compounds induce CYP1A1, CYP1A2, CYP2B1, and CYP2E1 (the last is also involved in the metabolism of tamoxifen) .'' &dquo;' Watercress, with its active compound phenylisothiocyanate (PEITC), is a strong inhibitor of CYP2E1,&dquo; as are garlic oil and some garlic compounds.&dquo; Chronic alcohol intake also induces CYP2E1, whereas acute intake inhibits it. '°I n addition to inducers and inhibitors, some commonly used (or abused) natural compounds can act as substrate competitors for certain CYP450 enzymes.
These include caffeine (a substrate of CYP1A2 and CYP2E 1 ) , alcohols (substrate of CYP2E 1 ) , and nicotine (substrate of CYP2A6).z°z' It is worth noting here that some commonly used no-prescription drugs are substrates of CYP450 enzymes: acetaminophen (CYP1A2,
CYP3A4) and dextromethorphan (CYP2D6) . 22
Other recent studies uncovering some potential drug-herb interactions must be viewed as preliminary. In vitro screening tests are available that examine the capacity of different substances to induce or inhibit CYP450 enzymes, and some of these have been applied to herbal medicines. Rosemary has been shown to inhibit CYP1A2 and CYP3A4 activities.2I Different compounds in Korean ginseng and other members of the genus Panax, known as ginsenosides, induce CYP3A4 and CYP2C9, or inhibit CYP3A4 in vitro; however, the relevance of these activities to the human situation was unclear and consequently they are not presented in the tables in this article.24 A recent in vitro study reported inhibition of CYP3A4 by several commonly used herbs (Saint John's wort, echinacea, goldenseal, cat's claw, licorice, chamomile, and red clover), again without any further investigation of the potential clinical significance.25 Other natural substances have also been tested in vitro for interactions with cytochrome enzymes. Capsaicin, the &dquo;hot&dquo; constituent of chili peppers, and ellagic acid, a constituent of berry fruits, both inhibited CYP450 enzymes, including 2A2, 3A1, found to inhibit CYP2D6.&dquo;' The clinical effects of SJW on cyclosporin are also consistent with an induction mechanism. Other than SJW, no clinical reports of drug interactions have been located for any of these natural substances, and their potential for significant interactions must be regarded as strictly theoretical.
Data on Cancer Treatment
Drugs Metabolized by CYP450 Bearing in mind the different levels of evidence for the biological effects of the various herbal medicines discussed, we have compiled in Tables 2 and 3 the literature on botanicals, foods, and lifestyle factors that may potentially affect drugs used in cancer treatment. Table 2 presents information on the drugs used for their anticancer effects (cytotoxic or hormonal), whereas Table 3 presents data on some ancillary drugs used in the supportive care of cancer patients. Each table shows the drugs; whether they are administered as prodrugs or active drugs; the enzymes for which they are substrates; the substances that are inducers, inhibitors, or substrate competitors for each enzyme; and the potential effects of induction, inhibition, and substrate competition.
Inducers, inhibitors, and competitors that are known to affect drug metabolism in humans are shown in boldface; SJW and grapefruit are the 2 so designated. Cruciferous vegetables and charcoal-grilled meats are shown in italics, as they are strongly suspected to metabolize xenobiotics on the basis of their epidemiological links to carcinogenesis. Watercress is in italics because of the noted strong activity of PEITC. ~ ~ No specific reports of effects on drug metabolism have been noted for these, however. Inducers, inhibitors, and competitors that have only experimental evidence are shown in regular type. It is notable in the table that the largest number of potential interactions is shown with CYP3A4, consistent with its role as a metabolizer of many important drugs.
For the 1 prodrug in Table 2 , ifosfamide, ingestion of a strong inducer could potentially activate more of the prodrug, or activate it more quickly, than usually anticipated, resulting in toxicity. In fact, tumor cells that overexpress CYP2B1 for local injection are now being investigated as potential treatments for cancers that are otherwise resistant to the effects of ifosfamide.
thus insufficient blood levels of active drug. Cyclophosphamide, a drug well known to be activated by the Cytochrome P450 system, is activated by the CYP2B system, for which no natural product inhibitors or inducers have been noted.' For the drugs in the table administered in the active form, the CYP3A4 inhibitors could, by deactivating the drug too rapidly, result in treatment failure.
Tamoxifen is the drug with the largest number of potential inhibitors and inducers that might affect therapeutic outcome. Among major inducers, which would result in treatment failure if their interactions were clinically significant, are charcoal-grilled meats, alcohol, high-fat diets, protein, nicotine, and cruciferous vegetables. Among inhibitors are watercress, grapefruit, and garlic, whereas caffeine, alcohol, and nicotine could act as competitors. The clinical significance of the variety of actors in the metabolism of patients treated with tamoxifen has yet to be explored. From the perspective of integrative care, patients on canceroriented vegetarian-type diets would be likely to increase their consumption of cruciferous vegetables and garlic. However, they would also be likely to decrease their consumption of meats, alcohol, fat, nicotine, and caffeine. One could speculate that the overall result, therefore, might be similar to the populations on whom initial tamoxifen dosage recommendations were developed, although no specific data on this question exist.
Clinical Significance
The first point to be made about the tables is that the only natural substances that have been observed to affect metabolism of drugs in humans are SJW and grapefruit, and, of these, SJW has not been actually observed to affect any drugs used in cancer treatment.
The other interactions we list are either theoretical, based on in vitro testing, or based on preliminary pharmacological research. Thus, it is unreasonable to conclude that, for instance, the several common herbs referred to in the table will all interfere with these drugs. It is even questionable to conclude that SJW will always have clinically relevant effects. For instance, Burstein the effects of omeprazole, a conventional drug for gastro-esophageal reflux that inhibits the CVYP2C subfamily and induces the CYP1A subfamily. The CYP1A induction of omeprazole would be expected to increase the liver toxicity of acetaminophen, although this is not reported clinically. However, the much stronger inducers, cigarette smoke and charcoal-grilled beef, are actually unable to alter acetaminophen metabolism.;' The effect of SJW on Table 2 .
Interactions of Cancer Chemotherapy Drugs With Natural Inhibitors and Inducers of CYP450 Enzymes
Grapefruit and SJW in bold type have reports of clmcally significant interactions with some drugs, not necessarily m this cancer drugs may depend on the pharmacological characteristics of each drug: cyclosporin, for instance, has a small therapeutic window and is known to be sensitive to medications that modulate CYP3A4. It is also sensitive to the modulation of P-glycoprotein expression-another system affected by SJW. 27 <¡ 1h The clinical impact of the inducers and inhibitors on these lists is thus difficult to predict at this time. Since docetaxel, one of the drugs known to be a substrate for CYP3A4, has been found to have outcomes that vary by patients' CYP3A4 levels, this might be a drug that might be clinically affected by an SJW interaction.&dquo; An additional complication is that other antidepressants also have potential drug interactions: fluoxetine, for instance, inhibits CPY2D6 and CYP2C19.1<J An interesting possibility, yet to be explored in experimental or clinical settings, is the use of CYP450 inducers or inhibitors to positively alter drug meta- Table 3 .
Interactions of Drugs Used in Supportive Care of Cancer Patients, With Natural Inhibitors and Inducers of CYP450 Enzymes
Grapefruit and SJW in bold type have reports of clmcally significant interactions with some drugs, not necessarily in this table. SJW = Saint John's wort.
bolism. For instance, a patient in whom docetaxel appeared to be ineffective, or whose CYP3A4 activity was known to be high, could be given grapefruit as an inhibitor to raise blood levels and potentially increase effectiveness-bearing in mind, of course, the risk of increased toxicity.
For now, however, use of inducers and inhibitors in adjusting the balance between treatment efficacy and toxicity must await further research. We are not able, either, to predict with certainly which of the potential interactions listed in these tables will prove to be of clinical relevance. However, it does seem reasonable to take into account clinically the inducers and inhibitors that are known to affect the metabolism of cancer drugs in making decisions about the use of food and herbal medicines during chemotherapy, because of the critical nature of cancer treatment. The physician caring for a depressed cancer chemotherapy patient who wishes to take SJW may need to weigh the potential drawbacks of temporarily changing the patient's antidepressant prescription to another drug against the potential, however uncertain, effect of causing increased toxicity or treatment failure, with potentially grave consequences.
